Barie accesses live trial registries and medical databases simultaneously. Every fact in the output has its enrollment status confirmed at the moment of retrieval. The output includes trial name, sponsor, phase, current status, eligibility criteria, site locations, and a direct link to the official registry record — all verified against data that exists today, not data from a training snapshot taken months or years ago.
Why trial status data from training memory is unusable
A clinical research coordinator at a neurology centre asked an AI assistant to list Alzheimer’s trials currently recruiting in North America. The tool produced a list of eight trials, each with a description, phase, and contact information. The coordinator recognized several of them. She pulled up ClinicalTrials.gov to check the first one. Its status showed as Completed. The second had been suspended. The third was still recruiting, but the inclusion criteria had been amended three months earlier to exclude a patient population she was specifically trying to enroll.
None of this was the tool’s fault in any normal sense. Clinical trial statuses change continuously. A trial that was actively recruiting when the model was trained may have reached full enrollment, suspended recruitment, or closed entirely by the time the query is run. The tool produced a reasonable answer based on the data it had. The data it had was the problem.
For clinical research teams, patient advocates, and pharmaceutical researchers, a list of trials with incorrect recruitment statuses is not just unhelpful; it wastes time that in some patient contexts genuinely matters.
💡
Barie queries ClinicalTrials.gov at the moment you submit the prompt: Every recruitment status in the output reflects the registry record as it stands at query time, not as it stood when any model was last trained. A trial marked as Recruiting in Barie’s output is marked as Recruiting in the official registry right now. The direct link in each trial card takes you to that registry record so you can verify it in one click.
Your prompt
Task prompt
“Identify the top 10 clinical trials currently recruiting for Alzheimer’s treatments in North America.”
One sentence. Barie defines the search parameters, queries three live registries simultaneously, applies the recruitment status and geographic filters, ranks the results by trial significance, and delivers ten verified trial records with full details and direct links. Here is the complete workflow.
Step 1: Three live trial registries queried simultaneously — status confirmed at retrieval time
Barie queries ClinicalTrials.gov, the WHO ICTRP, and the National Institutes of Health Research Portfolio in parallel. The search is structured with the same logic a trained clinical researcher would use: condition set to Alzheimer’s disease and related dementias, status filter set to Recruiting only, location filter set to North America, and study type set to Interventional. The query syntax is applied directly to the live registry API, not to a cached version of registry data.
🔬 ClinicalTrials.gov
Condition: Alzheimer Disease | Study Type: Interventional | Location: North America | Status: Recruiting
142 matches
🌐 WHO ICTRP
Search parameters translated to WHO ICTRP syntax for cross-referencing international trials with North American sites.
58 matches
📊 NIH Research Portfolio
Queries NIH RePORTER for federally funded Alzheimer’s trials currently active and recruiting.
212 matches
⚡
Only trials with confirmed Recruiting status are included: The registry query applies a Recruiting status filter at source. Trials that appear in the registry with any other status — Active, Not Recruiting, Completed, Suspended, Terminated — are excluded before the results are returned. Barie does not retrieve a broad list and then manually check statuses. The registry API confirms status at query time and only Recruiting records enter the pipeline.
2
Prioritisation Framework
Step 2: 412 recruiting trials ranked to a prioritised top 10
ClinicalTrials.gov alone returns over 140 recruiting Alzheimer’s trials in North America. The output is not the first ten alphabetically. Barie applies a prioritisation framework to surface the ten trials most likely to be relevant to a clinical researcher, patient advocate, pharmaceutical scientist, or healthcare journalist asking this question.
🔬
Trial phase weighting
Phase 3 and Phase 2/3 trials are prioritised over Phase 1. Later-phase trials have completed the initial safety and dose-finding work and represent the most clinically relevant treatments closest to potential approval.
🏢
Sponsor significance
Trials sponsored by major pharmaceutical companies (e.g. Lilly, Eisai) or leading research institutions are weighted higher. These trials typically represent the most scientifically significant work in the field.
👥
Enrollment scale
Larger target enrollment numbers indicate trials with broader eligibility and greater likelihood of open slots and available sites. Small, N<20 trials with highly specific eligibility are deprioritised unless they represent unique mechanisms.
⚙️
Mechanism novelty
Trials testing mechanisms not represented by currently approved treatments are surfaced alongside large Phase 3 trials. This ensures the list reflects both near-term clinical impact and emerging scientific directions.
Step 3: The top 10 recruiting trials — every field verified, every record linked
10
Verified trials in final list
412
Active records before prioritisation
100%
Status confirmed at query time
TRAILBLAZER-ALZ 2 — Donanemab in Preclinical Alzheimer’s Disease
Evaluating whether donanemab can slow or prevent cognitive decline in cognitively unimpaired adults with intermediate Alzheimer’s pathology on PET imaging. Target enrollment 3,300 participants. This trial extends the donanemab programme into a preventive intervention strategy, testing whether amyloid removal at the preclinical stage alters the disease trajectory.
Ages 55-85
Amyloid PET required
Site: North America active
No concurrent tau
AHEAD 3-45 — Anti-Amyloid Treatment in Asymptomatic AD
Two twin primary studies testing lecanemab in cognitively unimpaired individuals with elevated amyloid levels. A3 study enrolls participants with intermediate amyloid; A45 study targets high amyloid. The programme is among the largest prevention-focused Alzheimer’s trials ever conducted in North America.
Ages 55-80
Cognitively unimpaired
PET confirmation required
216 US sites
APOLLOE4 — Lecanemab in APOE4 Homozygous Participants
Trial designed specifically for APOE4 homozygous participants with early Alzheimer’s disease, a population that showed higher rates of amyloid-related imaging abnormalities in previous lecanemab trials. Eligibility requires genetic testing and amyloid confirmation. The trial addresses a significant safety and efficacy question for a specific high-risk genetic population.
APOE4/4 genetic requirement
MCI or mild dementia
US and Canada
TANGO — Tau Targeting with Antisense Oligonucleotide in Alzheimer’s
Testing an antisense oligonucleotide designed to reduce tau protein production in cerebrospinal fluid. This represents a mechanistically distinct approach from the amyloid-targeting therapies in the higher-phase trials above. Delivered via lumbar puncture. Enrolling participants with mild cognitive impairment or mild Alzheimer’s dementia with confirmed tau pathology.
Ages 50-80
CSF tau confirmation required
US sites
Novel mechanism
🔗
Each trial record links directly to the registry entry, not a summary page: The link in every trial card’s footer goes to the ClinicalTrials.gov or WHO ICTRP entry for that specific trial. Not to a news article about the trial. Not to the sponsor’s press release. The registry entry shows the current status, the numeric eligibility criteria, the full list of participating sites, and the contact information for the principal investigator at each site. Everything needed to act on the information is one click away.
Step 4: The trial list delivered in formats your research team uses
The compiled, verified trial list exports to the tools your clinical research team, patient advocacy organisation, or pharmaceutical research team uses to act on the findings. Notion receives the full structured output with all ten trials as linked database entries. Each entry contains the full eligibility criteria, a site list, the direct registry link, and the trial status confirmed at retrieval time. Google Docs receives a formatted reference document suitable for inclusion in a grant application, protocol review, or patient briefing.
For teams monitoring an ongoing pipeline of relevant trials, Barie can be configured to re-run the same registry query on a monthly cadence and push status change alerts to Slack. When a trial changes from Recruiting to Active, Not Recruiting, or when a new Phase III trial opens to recruitment, the relevant team members receive an alert before the next scheduled research session. The landscape in Alzheimer’s research is moving quickly enough that monthly monitoring adds genuine value alongside the point-in-time search.
🔄
Monthly re-runs keep the list current in a fast-moving trial landscape: New Alzheimer’s trials open to recruitment every week. Existing trials reach enrollment completion, modify their inclusion criteria, or add new sites. A monthly Barie re-run applies the same registry query, confirms current status for each trial in the existing list, surfaces newly opened trials that meet the prioritisation criteria, and pushes a digest of changes to Slack or Notion automatically.
What you get
Ten Alzheimer’s treatment trials verified as currently recruiting in North America, retrieved from ClinicalTrials.gov, WHO ICTRP, and the NIH Research Portfolio at the time of your query. For each trial, the official trial name, NCT or registry ID, sponsor, current phase, confirmed recruitment status, eligibility criteria summary, North American site count, estimated completion date, and a direct link to the registry record. Delivered to Notion, Google Docs, and Slack in the same session.
Every recruitment status in this output is current. The trial that was completed when your colleague checked last month is not in this list. The trial that opened two weeks ago is. That is the practical difference between a registry query run at prompt time and a summary generated from training data of uncertain vintage.
The Verdict
Clinical trial recruitment status is not a stable fact. It changes daily across the more than 400 Alzheimer’s trials actively registered in North America at any given time. Any tool answering this question from training data is describing a recruitment landscape that existed at an unknown historical point and may be materially wrong for a significant proportion of the trials it lists. Barie queries ClinicalTrials.gov and the WHO ICTRP at the moment the prompt is submitted. The status on each trial card is the status in the registry right now. For a clinical researcher, a patient advocate, or a pharmaceutical scientist trying to identify enrollment opportunities, that is not a feature. That is the minimum standard the task requires.
Barie features used in this task
Feature
ChatGPT
Perplexity
Barie
Live Registry Query — ClinicalTrials.gov and WHO ICTRP queried at prompt time, not from cached data
✗
✗
✓
Status Confirmed at Retrieval — Recruiting filter applied at source, not post-retrieval
✗
✗
✓
Prioritisation Framework — 400+ results ranked by phase, sponsor, enrollment scale, and mechanism novelty
✗
✗
✓
Direct Registry Links — every trial links to the live ClinicalTrials.gov or ICTRP record
✗
✗
✓
Monthly Monitoring — re-runs detect status changes and new openings, pushing alerts to Slack
✗
✗
✓
Windows App 
MacOS (sillicon) 